Search Results - "Kapitza, C."

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml by Becker, R. H. A., Nowotny, I., Teichert, L., Bergmann, K., Kapitza, C.

“…Aims To characterize the variability in exposure and metabolic effect of insulin glargine 300 U/ml (Gla‐300) at steady state in people with type 1 diabetes…”
Get full text

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin by Kapitza, C., Forst, T., Coester, H.-V., Poitiers, F., Ruus, P., Hincelin-Méry, A.

“…ABSTRACT Aim Assess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in type 2 diabetes insufficiently controlled on metformin…”
Get full text

The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment by Flint, A., Kapitza, C., Zdravkovic, M.

“…The aim was to investigate effects of liraglutide on appetite and energy intake in a randomized, placebo‐controlled, double‐blind, crossover study. Eighteen…”
Get full text

Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes - a study in both people with type 2 diabetes and healthy subjects by Becker, R. H. A., Stechl, J., Msihid, J., Kapitza, C.

“…Aims Glucagon‐like peptide‐1 (GLP‐1) receptor agonists improve blood glucose control by enhancing glucose‐sensitive insulin release, delaying gastric emptying…”
Get full text

Inter- and intra-rater-reliability of a clinical framework for spine-related neck-arm pain by Kapitza, C., Luedtke, K., Komenda, M., Kiefhaber, M., Schmid, A.B., Ballenberger, N., Tampin, B.

“…A mechanism-based clinical framework for spine-related pain differentiates (i) somatic referred pain, ii) heightened nerve mechanosensitivity, iii) radicular…”
Get full text

Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes by Heise, T., Morrow, L., Hompesch, M., Häring, H.-U., Kapitza, C., Abt, M., Ramsauer, M., Magnone, M.-C., Fuerst-Recktenwald, S.

“…Aims We assessed safety and efficacy of two selective 11β‐HSD1 inhibitors (RO5093151/RO‐151 and RO5027383/RO‐838) in this randomized, controlled study in…”
Get full text

How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes by Arnolds, S, Kuglin, B, Kapitza, C, Heise, T

“…This pedagogical review illustrates the differences between pharmacokinetic (PK) and pharmacodynamic (PD) measures, using insulin therapy as the primary…”
Get more information

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients by Dobbins, R. L., O'Connor-Semmes, R., Kapur, A., Kapitza, C., Golor, G., Mikoshiba, I., Tao, W., Hussey, E. K.

“…Aims: Remogliflozin etabonate (RE) is the pro‐drug of remogliflozin (R), a selective inhibitor of renal sodium‐dependent glucose transporter 2 (SGLT2) that…”
Get full text

Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study by Ratner, R., Nauck, M., Kapitza, C., Asnaghi, V., Boldrin, M., Balena, R.

“…The study objective was to investigate the safety and tolerability of up-titration to high doses of taspoglutide, a once-weekly human glucagon-like peptide-1…”
Get full text

Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes by Kapitza, C., Heise, T., Birman, P., Jallet, K., Ramis, J., Balena, R.

“…Aims  The study objectives were to evaluate the pharmacokinetic and pharmacodynamic properties, as well as safety and tolerability, of single doses of…”
Get full text

Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy by Meier, J. J., Pennartz, C., Schenker, N., Menge, B. A., Schmidt, W. E., Heise, T., Kapitza, C., Veldhuis, J. D.

“…Aim Postprandial insulin pulsatility is impaired in patients with type 2 diabetes, but the effects of exogenous insulin therapy on pulsatile insulin secretion…”
Get full text

Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes by Bott, S., Tusek, C., Jacobsen, L. V., Endahl, L., Draeger, E., Kapitza, C., Heise, T.

“…Aims  This study investigated the pharmacodynamic and pharmacokinetic characteristics of the novel long‐acting insulin analogue insulin detemir (IDet) under…”
Get full text

Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal by Kapitza, C., Rave, K., Ostrowski, K., Heise, T., Heinemann, L.

Get full text

Safety and tolerability of high doses of taspoglutide, a once‐weekly human GLP‐1 analogue, in diabetic patients treated with metformin: a randomized double‐blind placebo‐controlled study1,2 by Ratner, R., Nauck, M., Kapitza, C., Asnaghi, V., Boldrin, M., Balena, R.

“…Diabet. Med. 27, 556–562 (2010) Aims  The study objective was to investigate the safety and tolerability of up‐titration to high doses of taspoglutide, a…”
Get full text

Glucose monitoring by microdialysis: performance in a multicentre study by Nielsen, J. K., Freckmann, G., Kapitza, C., Ocvirk, G., Koelker, K. H., Kamecke, U., Gillen, R., Amann-Zalan, I., Jendrike, N., Christiansen, J. S., Koschinsky, T., Heinemann, L.

“…Aims  The aim of this study was to assess the performance of the Continuous Research Tool (CRT) in a multicentre clinical‐experimental study. Methods  Three…”
Get full text

Fotometrische Ermittlung der Position des Schultergürtels gesunder Probanden – eine deskriptive Studie by Kapitza, C., Schöttker-Königer, T., Schäfer, A.

“…Zusammenfassung Einleitung Die Relevanz der Haltung des Schultergürtels in Bezug auf dessen Funktion und die Funktion des Schultergelenkes ist vielfach in der…”
Get full text

P343 Faible variation d’exposition intra- et interjournalière de la nouvelle insuline glargine 300 U/ml chez des patients diabétiques de type 1 by Cariou, B, Halimi, S, Becker, R, Teichert, L, Bergmann, K, Kapitza, C

“…Rationnel Une faible variation d’exposition à l’insuline associée à une reproductibilité élevée sont nécessaires à une utilisation efficace et bien tolérée…”
Get full text

P330 Effets du lixisénatide vs liraglutide sur l’équilibre glycémique, la vidange gastrique et les critères de tolérance du traitement dans le diabète de type 2 (DT2) traité de façon optimisée par insuline glargine ± metformine by Guerci, B, Meier, J.J, Rosenstock, J, Hincelin-Mery, A, Roy-Duval, C, Delfolie, A, Coester, H.-V, Forst, T, Kapitza, C

“…Objectif Comparer la pharmacodynamie après un repas test et la tolérance du lixisénatide (LIXI) 20 µg vs liraglutide (LIRA) 1,2 et 1,8 mg par une étude…”
Get full text

PO13 Caractéristiques pharmacodynamiques du lixisénatide en une prise quotidienne vs le liraglutide chez des patients ayant un diabète de type 2 (DT2) non équilibré sous metformine by Kapitza, C, Coester, H, Poitiers, F, Heumann, G, Ruus, P, Hincelin-Méry, A

“…Objectif Cette étude randomisée, ouverte, avec administration répétée pendant 4 semaines, a comparé la pharmacodynamie du lixisénatide (20 µg par jour) vs le…”
Get full text

Time-action profile of the insulin analogue B28Asp by Heinemann, L, Kapitza, C, Starke, A A, Heise, T

Get more information